Showing results (2091-2100 of 2,109) with videos related to

Sort By:
Pageof 211
Annals of Translational Medicine|September 16, 2022
Efficacy and safety of esophagectomy via left thoracic approach versus via right thoracic approach for middle and lower thoracic esophageal cancer: a multicenter randomized clinical trial (NST1501)You-Sheng Mao, Shu-Geng Gao, Yin Li, et al.
Scientific Reports|January 13, 2016
The Dendrobium catenatum Lindl. genome sequence provides insights into polysaccharide synthase, floral development and adaptive evolutionGuo-Qiang Zhang, Qing Xu, Chao Bian, et al.
Nature Communications|November 9, 2021
Genomic signatures define three subtypes of EGFR-mutant stage II-III non-small-cell lung cancer with distinct adjuvant therapy outcomesSi-Yang Liu, Hua Bao, Qun Wang, et al.
Hepatology (Baltimore, Md.)|February 5, 2025
Multicenter, retrospective GUIDANCE001 study comparing transarterial chemoembolization with or without tyrosine kinase and immune checkpoint inhibitors as conversion therapy to treat unresectable hepatocellular carcinoma: Survival benefit in intermediate or advanced, but not early, stagesDa-Long Yang, Lin Ye, Fan-Jian Zeng, et al.
Liver Cancer|June 11, 2025
Survival Benefit of Hepatectomy after Complete or Partial Response to Conversion Therapy in Unresectable Hepatocellular Carcinoma (GUIDANCE003): A Multicenter StudyDa-Long Yang, Ning Peng, Jun-Liang Nong, et al.
Nature Genetics|November 25, 2014
The genome sequence of the orchid Phalaenopsis equestrisJing Cai, Xin Liu, Kevin Vanneste, et al.
Nature Metabolism|October 10, 2022
The aldolase inhibitor aldometanib mimics glucose starvation to activate lysosomal AMPKChen-Song Zhang, Mengqi Li, Yu Wang, et al.
Liver Cancer|January 19, 2026
Prognostic Usefulness of Clinical Complete Response after PD-1 Inhibitor-Based Combination Therapy for Unresectable Hepatocellular Carcinoma (GUIDANCE006)Liang Ma, Da-Long Yang, Teng-Meng Zhong, et al.
Nature|September 13, 2021
Virus-induced senescence is a driver and therapeutic target in COVID-19Soyoung Lee, Yong Yu, Jakob Trimpert, et al.
Liver Cancer|July 11, 2026
Real-World Efficacy and Safety of TACE Combined with Lenvatinib and PD-1 Inhibitor in Conversion Therapy for Unresectable Hepatocellular Carcinoma (GUIDANCE007): A Multicenter Retrospective StudyLin Ye, Guo-Xing Liu, Da-Long Yang, et al.
Pageof 211